Introduction - The discovery of sensitizing mutations in epidermal growth factor receptor (EGFR) and the rapid development of EGFR tyrosine kinase inhibitors (TKIs) have substantially changed the management of non-small-cell lung cancer (NSCLC), leading to a tailored therapeutic approach for patients ...
Therefore, the choice of many anticancer drugs is today the biggest issue for non-small cell lung cancer drug. 翻译结果2复制译文编辑译文朗读译文返回顶部 正在翻译,请等待... 翻译结果3复制译文编辑译文朗读译文返回顶部 So many anti-cancer drug, choose has drug for non-small cell lung cancer that...
Many patients with EGFR-mutated non-small cell lung cancer, or NSCLC, face a frustrating prognosis. While initial treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs) works well, “persister” cells that are left behind will almost certainly cause the cancer...
Therefore, the choice of many anticancer drugs is today the biggest issue for non-small cell lung cancer drug 翻译结果2复制译文编辑译文朗读译文返回顶部 正在翻译,请等待... 翻译结果3复制译文编辑译文朗读译文返回顶部 So many anti-cancer drug, choose has drug for non-small cell lung cancer that ...
The FDA today approved a new indication for ramucirumab for the treatment of metastatic non-small cell lung cancer. The FDA today approved a new indication for ramucirumab (Cyramza) for the treatment of metastatic non-small cell lung cancer (NSCLC). The drug was approved on April 21, 2014, ...
Single-agent anti-pyrimidine metabolism drugs gem has a good effect for non-small cell lung cancer, according to the reported single-agent efficacy of greater than or equal to 20%. 翻译结果2复制译文编辑译文朗读译文返回顶部 正在翻译,请等待... 翻译结果3复制译文编辑译文朗读译文返回顶部 GEM single...
Drug resistance is a major cause for therapeutic failure in non-small cell lung cancer (NSCLC) leading to tumor recurrence and disease progression. Cell intrinsic mechanisms of resistance include changes in the expression of drug transporters, activation of pro-survival, and anti-apoptotic pathways, ...
A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer R, Lopez-Ayllon BD, de Castro CJ, Belda-Iniesta C: A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer. ... R Perona,BD López-Ayllón,Javier de Castr...
were associated with clinical outcomes after treatment with a combination Gem/CDDP regimen for patients with advanced stage non-small cell lung cancer (NSCLC... RVN Lord,J Brabender,D Gandara,... - 《Clinical Cancer Research An Official Journal of the American Association for Cancer Research》 被...
Other immunotherapies for non-small-cell lung cancer, such as nivolumab and pembrolizumab, are designed to block PD-L1's counterpart, the programmed cell death protein 1 (PD-1) which is located on the immune cell surface. Normally the PD-L1 and PD-1 proteins signal to one another to activ...